Back to discover
Drug

Camrelizumab

In clinical development
ClassProgrammed cell death protein 1 antagonistEmerging researchLate-stage development

Also known as Carillizumab, Carrelizumab.

RxNorm2169823ChEMBLCHEMBL4297715UNII73096E137E
3
Research papers
80
Active clinical trials
Programmed cell death protein 1
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized, Open-Label, Multi-Center, Phase Ⅲ Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Clinical trial2026-07-31Primary completion · ClinicalTrials.gov

Camrelizumab, Apatinib Plus Hepatic Arterial Infusion Chemotherapy Versus Camrelizumab and Apatinib for Hepatocellular Carcinoma With Portal Vein Invasion: a Randomized, Open-label, Multicentre Trial

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Efficacy and Safety of PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

Clinical trial2026-07-01Primary completion · ClinicalTrials.gov

Clinical Study on the Combination of Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer Patients Who Have Received/Not Received Immunotherapy in the Past

Clinical trial2026-06-30Primary completion · ClinicalTrials.gov

A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer

Clinical trial2026-06-04Results expected Q3 2027 · ClinicalTrials.gov

Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Clinical trial2026-06-03Results expected Q4 2028 · ClinicalTrials.gov

A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence Factors

Clinical trial2026-06-01Results expected Q1 2027 · ClinicalTrials.gov

Efficacy and Safety of Camrelizumab Plus Albumin-bound Paclitaxel/Carboplatin Followed by Camrelizumab With or Without Fluzoparib Maintenance Therapy for TP-53 Mutated Recurrent or Metastatic Endometrial Cancer: A Phase II Trial

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Immune Checkpoint Inhibitors and Anti-Vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without Interventional Therapy for Advanced HCC

Clinical trial2026-06-01Primary completion · ClinicalTrials.gov

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.

Research2021-09-01JAMA

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial.

Research2020-10-21Clinical cancer research : an official journal of the American Association for Cancer Research

Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma.

Research2019-07-23Journal for immunotherapy of cancer

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Camrelizumab
Aliases & brands
CarillizumabCarrelizumab
RxNorm CUI
2169823
ChEMBL ID
CHEMBL4297715
UNII
73096E137E
Primary mechanism
Programmed cell death protein 1 antagonist

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Programmed cell death protein 1
PDCD1 · Q15116
ANTAGONISTProgrammed cell death protein 1 antagonist

Clinical trials

199 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
199
registered trials across all phases
LATEST COMPLETION 2026
80
Active studies
68
Recruiting
40
Late-stage (III+)
17
Completed
102
Discontinued
PHASE DISTRIBUTIONn = 199
Early Phase 11Phase 18Phase 1 / 213Phase 2137Phase 2 / 36Phase 317Phase N / A17

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Neoadjuvant Chemoimmunotherapy Combined With Surgery Versus Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: a Multicenter Randomized Controlled Clinical Trial

RecruitingPH II/IIITongji Hospitaln=4402031

Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Neoadjuvant Chemoradiotherapy Alone for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (NICE 2): a Multi-center, Randomized Phase II Trial

RecruitingPH IIIZhigang Lin=4262030

A Prospective, Randomized, Open-Label, Multicenter Phase III Trial Evaluating the Efficacy and Safety of Transarterial Chemoembolization Combined With an Oral Triple-Agent Cocktail Regimen Versus Transarterial Chemoembolization Combined With First-Line Targeted Therapy Plus Immunotherapy in Patients With Unresectable Hepatocellular Carcinoma

Not yet recruitingPH II/IIIShanghai Zhongshan Hospitaln=2222030

A Multicenter, Randomized Controlled Phase III Trial of Induction Plus Concurrent Chemoradiotherapy Plus Camrelizumab or Nimotuzumab Versus Induction Plus Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

RecruitingPH IIIFudan Universityn=4592028

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Resectable Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma: A Multicenter, Randomized Phase II-III Trial

Active, not recruitingPH II/IIIRuijin Hospitaln=5802027

Recent completions

Trials that read out recently, adding to the completed evidence base.

Randomized, Double-blind, Placebo-controlled, Multi-center Study of Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients of NSCLC With Brain Metastases of Driven Gene-negative and Not Received Systemic Chemotherapy

CompletedPH IIIGuangdong Association of Clinical Trialsn=602026

A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

CompletedPH IIChongqing University Cancer Hospitaln=392026

A Multicenter, Prospective, Double-Cohort Phase II Clinical Study of Camrelizumab in Combination With Docetaxel and Platinum or Apatinib Mesylate as First-Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

CompletedPH IIShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong Universityn=812025

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study

CompletedPH IIFujian Medical Universityn=1062025

Efficacy of Argon-Helium Cryoablation Combined With PD-1 Inhibitors in Non-Small Cell Lung Cancer: A Randomized Controlled Trial

CompletedN/AThe First Hospital of Hebei Medical Universityn=602024

A Randomized, Open-Label, Multi-Center, Phase 2 Clinical Study of Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

CompletedPH IIJiangsu HengRui Medicine Co., Ltd.n=2512024

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20192021
Journals, researchers & institutions
Top journals
  • Clinical cancer research : an official journal of the American Association for Cancer Research1
  • JAMA1
  • Journal for immunotherapy of cancer1
Leading researchers
  • Gu K2
  • Wu L2
  • Zhang H2
  • Zhang L2
  • Zhang X2
  • Zhang Y2
  • Ba Y1
  • Bai Y1
Leading institutions
free-text, unnormalised
  • 900 Hospital of the Joint Logistics Support Force2
  • Harbin Medical University Cancer Hospital2
  • Henan Cancer Hospital2
  • Hunan Cancer Hospital2
  • Jiangsu Cancer Hospital2
  • The First Affiliated Hospital of Anhui Medical University2

Related diseases

2 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Cisplatin

Studied across 4 of the same disease areas as Camrelizumab in the shared literature.

4 shared diseases1 shared paper
Apatinib

Studied across 2 of the same disease areas as Camrelizumab in the shared literature.

2 shared diseases1 shared paper
Paclitaxel

Studied across 2 of the same disease areas as Camrelizumab in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials